Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07174492 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Safety of Masitinib in Combination With SoC Versus Placebo in the Treatment of ALS Patients

StatusNot Yet Recruiting
PhasePhase 3
SponsorAB Science
Started
View on ClinicalTrials.gov ↗

Record History

  1. Interventions: Masitinib 4.5 mg/kg/day (Drug), Placebo (Drug) to Masitinib 4.5 mg/kg/day (Drug), Placebo (Drug), Riluzole (100 mg) (Drug) Study title shortened, about 1 wordv2 Show 1 more changeShow less
    • Study title shortened, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
AB Science
5 trials monitored
See all monitored trials
ALS
387 trials monitored
See 18 trials at risk
The objective is to compare the efficacy and safety of masitinib in combination with riluzole versus matched placebo in combination with riluzole for the treatment of Amyotrophic Lateral Sclerosis (ALS).
Trial Details
NCT Number NCT07174492
Lead Sponsor AB Science
Conditions Amyotrophic Lateral Sclerosis (ALS)
Enrollment 412 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov